Akamis Bio has secured $60m in funding, marking the close of a Series A Prime financing round, which will propel the development of its clinical candidate, NG-350A, for treating locally advanced rectal cancer (LARC), through study.
Candid Therapeutics has entered into a strategic research partnership with EpimAb Biotherapeutics to discover and develop new T-cell engagers (TCEs) for different types of autoimmune diseases.
Sanofi’s oral bioactive Bruton’s tyrosine kinase (BTK) inhibitor tolebrutinib has gained breakthrough therapy designation from the US Food and Drug Administration (FDA) for treating the adult population with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Tanner Pharma has partnered with Agenus to offer expanded access to investigational immunotherapies, botensilimab (BOT) and balstilimab (BAL), for individuals with microsatellite stable colorectal cancer (MSS CRC) and other advanced solid tumours.
ProQR Therapeutics has expanded its partnership with the Rett Syndrome Research Trust (RSRT), receiving an additional $8.1m in funding to support the advancement of Rett Syndrome therapy, AX-2402 into clinical trials.
Orthogon Therapeutics has closed an oversubscribed $5.2m in funding to expedite the development of new treatments for handling the reactivation of BK virus in transplant patients.
The US Food and Drug Administration (FDA) has accepted Crinetics Pharmaceuticals' paltusotine new drug application (NDA) as a long-term maintenance and potential treatment for acromegaly in the adult population.
Torii Pharmaceutical has submitted a new drug application (NDA) for TO-208 in Japan, targeting the treatment of molluscum contagiosum, a common and highly contagious skin disease.
Mind Medicine (MindMed) has received the innovation passport designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its MM120 Orally Disintegrating Tablet (ODT) as a potential treatment for generalised anxiety disorder (GAD).
Theratechnologies has entered into a licensing agreement with Ionis Pharmaceuticals to acquire exclusive Canadian rights for two investigational RNA-targeted medicines, olezarsen and donidalorsen.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.